Literature DB >> 23257291

SREBP: a novel therapeutic target.

Xu Xiao1, Bao-Liang Song.   

Abstract

Sterol regulatory element-binding proteins (SREBPs) are major transcription factors regulating the biosynthesis of cholesterol, fatty acid, and triglyceride. They control the expression of crucial genes involved in lipogenesis and uptake. In this review, we summarize the processing of SREBPs and their regulation by insulin, cAMP, and vitamin A, and the relationship between miRNA and lipid metabolism. We also discuss the recent functional studies on SREBPs. These discoveries suggest that inhibition of SREBP can be a novel strategy to treat metabolic diseases, such as type II diabetes, insulin resistance, fatty liver, and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23257291     DOI: 10.1093/abbs/gms112

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  28 in total

1.  A negative feedback loop between microRNA-378 and Nrf1 promotes the development of hepatosteatosis in mice treated with a high fat diet.

Authors:  Tianpeng Zhang; Xiaoling Zhao; Clifford J Steer; Guiqin Yan; Guisheng Song
Journal:  Metabolism       Date:  2018-04-03       Impact factor: 8.694

2.  Atheroprone flow activation of the sterol regulatory element binding protein 2 and nod-like receptor protein 3 inflammasome mediates focal atherosclerosis.

Authors:  Jun-ichi Abe; Bradford C Berk
Journal:  Circulation       Date:  2013-07-09       Impact factor: 29.690

Review 3.  Flow signaling and atherosclerosis.

Authors:  Nhat-Tu Le; Uday G Sandhu; Raymundo A Quintana-Quezada; Nguyet Minh Hoang; Keigi Fujiwara; Jun-Ichi Abe
Journal:  Cell Mol Life Sci       Date:  2016-12-30       Impact factor: 9.261

4.  Estrogen Mediates an Atherosclerotic-Protective Action via Estrogen Receptor Alpha/SREBP-1 Signaling.

Authors:  Fei Xie; Xiandong Li; Yue Xu; Dongliang Cheng; Xianru Xia; Xi Lv; Guolin Yuan; Chunyan Peng
Journal:  Front Cardiovasc Med       Date:  2022-07-05

5.  The possible antidiabetic effects of vitamin D receptors agonist in rat model of type 2 diabetes.

Authors:  Wafaa M Abdel-Rehim; Rasha A El-Tahan; Mennatullah A El-Tarawy; Rowaida R Shehata; Maher A Kamel
Journal:  Mol Cell Biochem       Date:  2018-06-16       Impact factor: 3.396

6.  Identification of miR-185 as a regulator of de novo cholesterol biosynthesis and low density lipoprotein uptake.

Authors:  Muhua Yang; Weidong Liu; Christina Pellicane; Christine Sahyoun; Biny K Joseph; Christina Gallo-Ebert; Melissa Donigan; Devanshi Pandya; Caroline Giordano; Adam Bata; Joseph T Nickels
Journal:  J Lipid Res       Date:  2013-12-02       Impact factor: 5.922

Review 7.  The microRNA-183 cluster: the family that plays together stays together.

Authors:  Shweta Dambal; Mit Shah; Brittany Mihelich; Larisa Nonn
Journal:  Nucleic Acids Res       Date:  2015-07-13       Impact factor: 16.971

8.  Altering cancer transcriptomes using epigenomic inhibitors.

Authors:  Malaina Gaddis; Diana Gerrard; Seth Frietze; Peggy J Farnham
Journal:  Epigenetics Chromatin       Date:  2015-02-24       Impact factor: 4.954

9.  Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia.

Authors:  Michael H Davidson
Journal:  EBioMedicine       Date:  2015-03-09       Impact factor: 8.143

10.  ABCC6- a new player in cellular cholesterol and lipoprotein metabolism?

Authors:  Patricia Kuzaj; Joachim Kuhn; Mareike Dabisch-Ruthe; Isabel Faust; Christian Götting; Cornelius Knabbe; Doris Hendig
Journal:  Lipids Health Dis       Date:  2014-07-27       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.